Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Segment Information (Tables)

v3.3.1.900
Note 3 - Segment Information (Tables)
 6 Months Ended
Dec. 31, 2015
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
 
 
Quarter Ended
 
 
Six Months Ended
 
 
 
December 31,
 
 
December 31,
 
 
 
2015
 
 
2014
 
 
2015
 
 
2014
 
Net sales:
                                
Biotechnology
   $ 75,854     $ 74,373     $ 151,597     $ 150,807  
Clinical Controls
     25,723       17,297       46,085       36,406  
Protein Platforms
     19,337       20,478       35,634       33,382  
Intersegment
     (7
)
     (200
)
     (28
)
     (190
)
Consolidated net sales
   $ 120,907    
$
 111,948     $ 233,288     $ 220,425  
                                 
Segment operating income:
                                
Biotechnology
   $ 39,986     $ 38,038     $ 79,302     $ 78,465  
Clinical Controls
     7,297       5,128       12,010       11,238  
Protein Platforms
     1,528       3,447       356       6,050  
Segment operating income
     48,811       46,613       91,668       95,753  
                                 
Costs recognized on sale of acquired inventory
     (1,245
)
     (1,188
)
     (2,357
)
     (4,356
)
Amortization of acquisition related intangible assets
     (7,361
)
     (6,858
)
     (14,772
)
     (12,586
)
Acquisition related expenses
     (670
)
     (1,201
)
     (970
)
     (3,571
)
Stock based compensation
     (2,321
)
     (2,075
)
     (4,359
)
     (3,437
)
Corporate general, selling, and administrative
     (1,189
)
     (711
)
     (2,156
)
     (2,007
)
Operating income
   $ 36,025     $ 34,580     $ 67,054     $ 69,796